REGN Regeneron Pharmaceuticals, Inc.
$816.10▲ +1.04%
Healthcare
Other
After hours
$816.10▲ +0.00%
Oct 27, 5:25 PM ET
Volume 716.9K
Avg Volume (10D) 645.8K
Key Metrics & Fundamentals
Market Cap
$84.02B
P/E Ratio
20.2
Div Yield
0.47%
52W Range
591.52 - 859.34
% vs 50 MA
3.09%
% vs 200 MA
10.86%
RSI-14
61.1
MACD Histogram
+6.2600
Beta (1Y vs SPY)
0.47
Free Cash Flow
$521.80M
Gross Rev
$4.29B
Gross Profit
$3.71B
EBITDA
$1.73B
COGS
$576.50M
Operating Exp
$2.29B
Operating Income
$1.42B
EBIT
$1.42B
Pretax Income
$1.53B
Net Income
$1.30B
EPS (Diluted)
12.23
Price & Volume History
Loading chart…
Recent News
Missed Regeneron Pharmaceuticals' Rally? Here Is The Bull Case
Simply Wall St. · Oct 27, 2026 8:16 PM ET
Has Regeneron Stock Become A Different Bet?
Trefis · Oct 27, 2026 12:44 PM ET
Regeneron agrees to $270m extension to supply Ebola medicine in US
Pharmaceutical Technology · Oct 27, 2026 6:54 AM ET
Fed Meeting, More Tech Earnings: What to Watch This Week
The Wall Street Journal · Oct 27, 2026 4:02 AM ET
Regeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For Libtayo
Simply Wall St. · Oct 27, 2026 3:09 AM ET
Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings
24/7 Wall St. · Oct 26, 2026 9:39 AM ET
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
Zacks · Oct 26, 2026 9:00 AM ET
Regeneron Pharmaceuticals Extends Deal to Provide Ebola Treatment to US Government for $270 Million
MT Newswires · Oct 26, 2026 8:01 AM ET
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
GlobeNewswire · Oct 26, 2026 7:00 AM ET
Can Incyte Stock Hit $170?
Trefis · Oct 26, 2026 6:13 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See REGN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.